SOSV

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

Alternative Plants is a biotech start-up that establishes plant stem cell cultures for effective, consistent and sustainable production of cosmetic active ingredients. Our focus is on medicinal plants that are difficult to grow, are rare or even endangered, so our plant stem cell culture technology is the only way to access the valuable substances that they produce. Our current focus is on cosmetic active ingredients market. Our clients are cosmetic manufacturers that use our plant stem cell derived active substances as key active ingredients in their products. In the same time we clearly see that with our technology we can later expand to other markets as functional foods, medical devices and pharma as well.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

Innatrix is an agricultural biotechnology company developing novel biological and chemical products based on patented protein evolution technology, to control untreatable crop diseases, pests, and weeds.

Innatrix is an agricultural biotechnology company developing novel biological and chemical products based on patented protein evolution technology, to control untreatable crop diseases, pests, and weeds.

PluriCell wants to positively impact the lives of millions of patients suffering from chronic heart failure condition by injecting healthy bona fide lab-made human heart cells in their failing heart, improve its function and, ultimately, the clinical outcome of the patients. Our tech enables us not only tackle heart diseases, but potentially, many chronic disorders currenly untractable.

Filtricine, Inc. is a clinical-stage biotechnology company based in Santa Clara, California, focused on developing therapeutic products for cancer treatment. Founded in 2017, the company specializes in a novel nutrient modulation platform that targets and depletes essential nutrients critical for cancer cell growth. By exploiting the metabolic vulnerabilities of cancer cells, Filtricine aims to halt the spread of cancer without relying on traditional drug substances. This approach allows healthcare professionals to utilize targeted nutrient deprivation therapy to address a broad spectrum of cancers effectively.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

Diadem Biotherapeutics is a biotechnology company that focuses on creating bio-therapeutical materials produced using organic means. Diadem develops exosomes to treat chronic inflammatory and auto-immune conditions.

CyGenica uses a non-viral, non-toxic platform to develop in vitro and in vivo delivery solutions for drugs, gene editing components, and antibiotics.

Inflammatory disease affects us all. We looked 300 million years into our past to imagine a healthier future, beyond the limitations of today’s anti-inflammatory drugs. Lupa Bio is developing an entirely new class of safer, anti-inflammatory therapeutics based on compounds found in mothers’ milk ...because no technology today can screen like the forces of nature. ​

Pregenerate, Inc. is a biotechnology company founded in 2019 and incorporated in Delaware. It specializes in developing scalable organ-on-a-chip models aimed at replacing animal testing in medical and pharmaceutical research, particularly for arthritis treatments. By utilizing human cells in its innovative models, Pregenerate's technology not only enhances the efficiency of drug development but also improves success rates for bringing new medications to market. Furthermore, this approach allows for the stratification of patients into specific treatment subgroups, enabling healthcare providers to tailor therapies to individual needs. This focus on personalized medicine aims to significantly reduce the costs associated with traditional testing methods while advancing the understanding of treatment responses in patients with arthritis.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

Pregenerate, Inc. is a biotechnology company founded in 2019 and incorporated in Delaware. It specializes in developing scalable organ-on-a-chip models aimed at replacing animal testing in medical and pharmaceutical research, particularly for arthritis treatments. By utilizing human cells in its innovative models, Pregenerate's technology not only enhances the efficiency of drug development but also improves success rates for bringing new medications to market. Furthermore, this approach allows for the stratification of patients into specific treatment subgroups, enabling healthcare providers to tailor therapies to individual needs. This focus on personalized medicine aims to significantly reduce the costs associated with traditional testing methods while advancing the understanding of treatment responses in patients with arthritis.

SyntheX, Inc. operates a screening platform to discover and design drugs for therapeutic and biotechnological applications. The company’s development portfolio includes STX101 and STX105, which are stabilized peptide therapeutics for specific types of cancers, which are dependent on homologous recombination for chemo evasion. It identifies relevant drug targets based on clinical, evolutionary, phenotypic, and structural features. The company was founded in 2016 and is based in San Francisco, California.

ANA Therapeutics is a developer of a novel coronavirus vaccine intended to save human lives. It is developing therapeutics to solve the coronavirus pandemic using Niclosamide that enables medical practitioners to treat patients suffering from COVID-19. It was founded in 2020 and is headquartered in Foster City, California.

Inflammatory disease affects us all. We looked 300 million years into our past to imagine a healthier future, beyond the limitations of today’s anti-inflammatory drugs. Lupa Bio is developing an entirely new class of safer, anti-inflammatory therapeutics based on compounds found in mothers’ milk ...because no technology today can screen like the forces of nature. ​

Developing hardware for manufacturing next-generation medicines.

Developing hardware for manufacturing next-generation medicines.

ANA Therapeutics is a developer of a novel coronavirus vaccine intended to save human lives. It is developing therapeutics to solve the coronavirus pandemic using Niclosamide that enables medical practitioners to treat patients suffering from COVID-19. It was founded in 2020 and is headquartered in Foster City, California.

sRNAlytics developed a computational platform to diagnose and subtype disease using small RNAs. We offer our technology and services to drug developers to identify companion diagnostics and uncover new therapeutic targets.

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

Sothic Bioscience Ltd. operates as a biotech company in Ireland. The company develops LimuleX, a bio-production platform to make bio-identical replacement for naturally sourced limulus amebocyte lysate, as well as to remove the threatened horseshoe crab species from the pharmaceutical quality control supply chain. Sothic Bioscience Ltd. was founded in 2015 and is based in Cork, Ireland.

Inflammatory disease affects us all. We looked 300 million years into our past to imagine a healthier future, beyond the limitations of today’s anti-inflammatory drugs. Lupa Bio is developing an entirely new class of safer, anti-inflammatory therapeutics based on compounds found in mothers’ milk ...because no technology today can screen like the forces of nature. ​

Diadem Biotherapeutics is a biotechnology company that focuses on creating bio-therapeutical materials produced using organic means. Diadem develops exosomes to treat chronic inflammatory and auto-immune conditions.

sRNAlytics developed a computational platform to diagnose and subtype disease using small RNAs. We offer our technology and services to drug developers to identify companion diagnostics and uncover new therapeutic targets.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

Beeline is an early-stage preclinical cell therapy company developing the next generation of immune cell therapies for immune-mediated human disease, particularly diseases which result from the patient's own immune cells attacking healthy tissue. We are genetically engineering a patient's own immune cells to secrete therapeutic proteins in vivo and induce tolerance. In particular, we are re-engineering Regulatory T cells (Tregs) to produce optimal quantities of immunomodulatory cytokines, antibodies, and other therapeutic proteins, and combining enhanced Treg function with antigen specificity via targeting receptors for improved localization.

Bioptamers, Inc. specializes in the development of cellular and gene therapies aimed at treating cancer. Founded in 2018 and headquartered in New Castle, Delaware, with an additional office in São Paulo, Brazil, the company focuses on innovative therapeutic delivery technologies using monoclonal antibodies and antibody-drug conjugates. Bioptamers is creating a platform to optimize aptamer selection, allowing for personalized cancer therapy tailored to individual patient needs. The company aims to transform these specialized molecules into valuable clinical products, which will be licensed to pharmaceutical companies for further development and commercialization.

Serenity is improving the production and performance of protein-based therapeutics. Serenity Bioworks has large plans for the pharmaceutical industry. Their overall aim is to actualize innovative ideas that will improve the healthcare system for all parties involved. Serenity's first offering is a novel stabilization platform for biologics, called CargoTek. CargoTek has a great potential to enhance the long-term efficacy and safety profiles for biologics, resulting in safe and longer-lasting treatments for patients.

11 Biomics LLC develops biological therapeutics for the cannabis industry. It offers small and large scale treatment and protection against fungal and bacterial diseases in cannabis and hemp. The company is based in Albuquerque, New Mexico.

Pregenerate, Inc. is a biotechnology company founded in 2019 and incorporated in Delaware. It specializes in developing scalable organ-on-a-chip models aimed at replacing animal testing in medical and pharmaceutical research, particularly for arthritis treatments. By utilizing human cells in its innovative models, Pregenerate's technology not only enhances the efficiency of drug development but also improves success rates for bringing new medications to market. Furthermore, this approach allows for the stratification of patients into specific treatment subgroups, enabling healthcare providers to tailor therapies to individual needs. This focus on personalized medicine aims to significantly reduce the costs associated with traditional testing methods while advancing the understanding of treatment responses in patients with arthritis.

Filtricine, Inc. is a clinical-stage biotechnology company based in Santa Clara, California, focused on developing therapeutic products for cancer treatment. Founded in 2017, the company specializes in a novel nutrient modulation platform that targets and depletes essential nutrients critical for cancer cell growth. By exploiting the metabolic vulnerabilities of cancer cells, Filtricine aims to halt the spread of cancer without relying on traditional drug substances. This approach allows healthcare professionals to utilize targeted nutrient deprivation therapy to address a broad spectrum of cancers effectively.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

Osiris Therapeutics, Inc. is a biotechnology company specializing in regenerative medicine, focusing on the development and marketing of cellular products aimed at treating various medical conditions, including those related to inflammation, cardiovascular health, orthopedics, and wound healing. The company operates through two main segments: Therapeutics and Biosurgery. Its Therapeutics segment emphasizes the development of biologic stem cell drug candidates sourced from readily available and non-controversial materials. Osiris markets its products under several brand names, including Grafix, GrafixPL, Stravix, Cartiform, and BIO4. Founded in 1992 and based in Columbia, Maryland, Osiris has established partnerships with organizations such as the Department of Veterans Affairs, Department of Defense, Howmedica Osteonics Corp., and Mesoblast Limited. As of April 2019, Osiris operates as a subsidiary of Smith & Nephew plc, enhancing its capacity to improve patient health while aiming to reduce overall healthcare costs.

Serenity is improving the production and performance of protein-based therapeutics. Serenity Bioworks has large plans for the pharmaceutical industry. Their overall aim is to actualize innovative ideas that will improve the healthcare system for all parties involved. Serenity's first offering is a novel stabilization platform for biologics, called CargoTek. CargoTek has a great potential to enhance the long-term efficacy and safety profiles for biologics, resulting in safe and longer-lasting treatments for patients.

Filtricine, Inc. is a clinical-stage biotechnology company based in Santa Clara, California, focused on developing therapeutic products for cancer treatment. Founded in 2017, the company specializes in a novel nutrient modulation platform that targets and depletes essential nutrients critical for cancer cell growth. By exploiting the metabolic vulnerabilities of cancer cells, Filtricine aims to halt the spread of cancer without relying on traditional drug substances. This approach allows healthcare professionals to utilize targeted nutrient deprivation therapy to address a broad spectrum of cancers effectively.

Vetherapy is a biotechnology company based in San Francisco, California, specializing in veterinary regenerative medicine and tissue engineering. Founded in 2015, the company develops stem cell therapy products for cats, dogs, and horses, aimed at accelerating wound healing and treating autoimmune and inflammatory diseases. Vetherapy emphasizes quality and safety in its processes, which include the isolation, expansion, and cryopreservation of stem cells, as well as the preparation of platelet-rich plasma. By providing veterinarians with access to a stem cell and PRP bank through their cryopreservation services, Vetherapy ensures that these therapeutic products are readily available for immediate use, addressing various clinical needs for animal patients.

Nivien Therapeutics is a Boston-based company founded in 2016 that focuses on developing innovative treatments for patients suffering from resistant cancers. The company has pioneered the creation of the first small molecule inhibitors of the Hippo signaling pathway, which are designed to enhance both chemotherapy and immunotherapy. Nivien Therapeutics is committed to advancing its unique platform that improves the efficacy of immuno-oncology and chemotherapy combinations, particularly for patients who do not respond to conventional treatments. By collaborating with top research institutes, the company aims to de-risk the transfer of technology assets and build a robust portfolio of biotechnology investments.

sRNAlytics developed a computational platform to diagnose and subtype disease using small RNAs. We offer our technology and services to drug developers to identify companion diagnostics and uncover new therapeutic targets.

Onconetics Pharmaceuticals, Inc. is a biotech company focused on developing innovative gene therapies aimed at targeting tumor cells based on specific gene expression profiles. By utilizing a genetic switch to activate an apoptotic inducer, the therapies aim to eliminate cancer cells while preserving healthy tissue. Founded in 2016 and located in Mill Valley, California, the company is dedicated to advancing personalized medicine, particularly in the treatment of cancer and genetic disorders. Onconetics combines established gene therapy techniques with cutting-edge research to create novel treatments that seek to minimize the invasiveness, cost, and uncertainty associated with traditional cancer therapies. The goal is to develop simpler and more versatile personalized therapies that maintain patient quality of life and enhance understanding of genetic conditions.

Hyasynth Bio is a Montreal-based company that specializes in the production of natural cannabinoid compounds. It focuses on developing innovative solutions for researchers, healthcare professionals, and patients dealing with conditions such as multiple sclerosis, epilepsy, Alzheimer's disease, chronic pain, inflammation, and muscular dystrophy. By leveraging a combination of traditional and modern biological technologies along with computational analysis, Hyasynth Bio aims to create effective drugs for a wide range of diseases. The company utilizes a scalable platform based on engineered microbes to enhance its drug development process, effectively addressing the needs of the medical community.

Our mission is to discover novel therapeutics for diseases with the highest unmet need, pushing the boundaries of drug discovery through innovative and world-class science. Our award-winning small-molecule drug discovery platform uniquely integrates a novel synthesis design strategy, computational modelling, and patient-derived cell-based screening to rapidly and cost-effectively unlock targets considered undruggable using existing approaches. Proteorex’s headquarters are in JLABS @ Toronto, with an office in San Francisco.

Phyteau is developing a new class of therapeutics for diabetes, obesity, weight-loss, and related metabolic condition like NAFLD and NASH. The company's therapeutics work in the intestines where they trigger key cellular receptors causing the release of therapeutic levels of key metabolic hormones, like GLP-1, PYY and CCK. The hormones work naturally and safely to control blood sugar, appetite, food intake, and metabolism. The company continues to develop new solutions to help people around the world suffering from metabolic diseases. Phyteau was founded on 2017 and is headquartered in Santa Fe, New Mexico.

Stelvio Oncology, founded in 2017 and based in San Francisco, California, specializes in developing therapeutics for glioblastoma, an aggressive form of brain cancer. The company focuses on converting glioblastoma multiforme tumor cells into healthy cells by leveraging unique epigenetic signatures associated with specific cell types. Stelvio employs advanced technologies, including microscopic imaging of epigenetic landscapes, to identify small molecules that can induce differentiation or reverse cancerous cells into benign states. This personalized approach aims to provide innovative treatment options for glioblastoma patients, combining scientific creativity with clinical expertise to advance drug therapies and precision medicine diagnostics.

PSG Therapeutics

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

Alternative Plants is a biotech start-up that establishes plant stem cell cultures for effective, consistent and sustainable production of cosmetic active ingredients. Our focus is on medicinal plants that are difficult to grow, are rare or even endangered, so our plant stem cell culture technology is the only way to access the valuable substances that they produce. Our current focus is on cosmetic active ingredients market. Our clients are cosmetic manufacturers that use our plant stem cell derived active substances as key active ingredients in their products. In the same time we clearly see that with our technology we can later expand to other markets as functional foods, medical devices and pharma as well.

SyntheX, Inc. operates a screening platform to discover and design drugs for therapeutic and biotechnological applications. The company’s development portfolio includes STX101 and STX105, which are stabilized peptide therapeutics for specific types of cancers, which are dependent on homologous recombination for chemo evasion. It identifies relevant drug targets based on clinical, evolutionary, phenotypic, and structural features. The company was founded in 2016 and is based in San Francisco, California.

Hyasynth Bio is a Montreal-based company that specializes in the production of natural cannabinoid compounds. It focuses on developing innovative solutions for researchers, healthcare professionals, and patients dealing with conditions such as multiple sclerosis, epilepsy, Alzheimer's disease, chronic pain, inflammation, and muscular dystrophy. By leveraging a combination of traditional and modern biological technologies along with computational analysis, Hyasynth Bio aims to create effective drugs for a wide range of diseases. The company utilizes a scalable platform based on engineered microbes to enhance its drug development process, effectively addressing the needs of the medical community.

A2A Pharmaceuticals, Inc. operates as a biotechnology company. It focuses on the development of novel drugs for treating antibiotic-resistant bacterial infections, tuberculosis, and cancer. The company applies its therapeutic design methodology to inhibiting protein-protein interactions; and bioinformatics methodology to gram-negative bacterial species. It also offers consulting services. The company was founded in 2016 and is headquartered in New York, New York.

A2A Pharmaceuticals, Inc. operates as a biotechnology company. It focuses on the development of novel drugs for treating antibiotic-resistant bacterial infections, tuberculosis, and cancer. The company applies its therapeutic design methodology to inhibiting protein-protein interactions; and bioinformatics methodology to gram-negative bacterial species. It also offers consulting services. The company was founded in 2016 and is headquartered in New York, New York.

BlueTurtleBio Technologies creates a next generation therapeutic using a patent pending platform technology. The company's mission is the golden triangle of healthcare: safety, effectiveness and affordability. Most healthcare options miss one or more of these standards. At Blue Turtle, they plan to recruit a genetically malleable and easily replenishable organ in the human body: the microbiome.

Cell Reserves Inc. manufactures protein and peptide-based therapeutics for the treatment of diseases. It manufactures bio-pharmaceuticals using molecular shields that increase the bio-availability of therapeutics in circulation. Cell Reserves Inc. is based in Ottawa, Canada.

Sothic Bioscience Ltd. operates as a biotech company in Ireland. The company develops LimuleX, a bio-production platform to make bio-identical replacement for naturally sourced limulus amebocyte lysate, as well as to remove the threatened horseshoe crab species from the pharmaceutical quality control supply chain. Sothic Bioscience Ltd. was founded in 2015 and is based in Cork, Ireland.

SyntheX, Inc. operates a screening platform to discover and design drugs for therapeutic and biotechnological applications. The company’s development portfolio includes STX101 and STX105, which are stabilized peptide therapeutics for specific types of cancers, which are dependent on homologous recombination for chemo evasion. It identifies relevant drug targets based on clinical, evolutionary, phenotypic, and structural features. The company was founded in 2016 and is based in San Francisco, California.

Hyasynth Bio is a Montreal-based company that specializes in the production of natural cannabinoid compounds. It focuses on developing innovative solutions for researchers, healthcare professionals, and patients dealing with conditions such as multiple sclerosis, epilepsy, Alzheimer's disease, chronic pain, inflammation, and muscular dystrophy. By leveraging a combination of traditional and modern biological technologies along with computational analysis, Hyasynth Bio aims to create effective drugs for a wide range of diseases. The company utilizes a scalable platform based on engineered microbes to enhance its drug development process, effectively addressing the needs of the medical community.

Sothic Bioscience Ltd. operates as a biotech company in Ireland. The company develops LimuleX, a bio-production platform to make bio-identical replacement for naturally sourced limulus amebocyte lysate, as well as to remove the threatened horseshoe crab species from the pharmaceutical quality control supply chain. Sothic Bioscience Ltd. was founded in 2015 and is based in Cork, Ireland.

BlueTurtleBio Technologies creates a next generation therapeutic using a patent pending platform technology. The company's mission is the golden triangle of healthcare: safety, effectiveness and affordability. Most healthcare options miss one or more of these standards. At Blue Turtle, they plan to recruit a genetically malleable and easily replenishable organ in the human body: the microbiome.

Hyasynth Bio is a Montreal-based company that specializes in the production of natural cannabinoid compounds. It focuses on developing innovative solutions for researchers, healthcare professionals, and patients dealing with conditions such as multiple sclerosis, epilepsy, Alzheimer's disease, chronic pain, inflammation, and muscular dystrophy. By leveraging a combination of traditional and modern biological technologies along with computational analysis, Hyasynth Bio aims to create effective drugs for a wide range of diseases. The company utilizes a scalable platform based on engineered microbes to enhance its drug development process, effectively addressing the needs of the medical community.

Hyasynth Bio is a Montreal-based company that specializes in the production of natural cannabinoid compounds. It focuses on developing innovative solutions for researchers, healthcare professionals, and patients dealing with conditions such as multiple sclerosis, epilepsy, Alzheimer's disease, chronic pain, inflammation, and muscular dystrophy. By leveraging a combination of traditional and modern biological technologies along with computational analysis, Hyasynth Bio aims to create effective drugs for a wide range of diseases. The company utilizes a scalable platform based on engineered microbes to enhance its drug development process, effectively addressing the needs of the medical community.